Supply Rivaroxaban raw Materials powder

CAS:366789-02-8

MF:C19H18ClN3O5S

MW:435.88

EINECS:685-132-2

Specification: 99% min Rivaroxaban powder

Sample:Rivaroxaban powder

Packaging:1kg/bag, 25kg/drum

Brand:Henrikang

Appearance:white

Storage: Cool Dry Place

Shelf Life: 2 Years

Test Method: HPLC

Rivaroxaban powder Usage and Synthesis.

New anticoagulants were first used for thrombosis prevention after orthopedic surgery, including total hip and knee replacement surgery, and its effectiveness and safety have been reported to be no worse than low molecular weight heparin. Nowadays, new anticoagulants are gradually widely used in the treatment of venous thrombosis and pulmonary embolism in the lower extremities. In 2014, it was mentioned in the latest diagnosis and treatment guidelines of acute pulmonary embolism formulated by ESC that new anticoagulants can be used as an emerging anticoagulant drug to replace traditional anticoagulant therapy, and will be gradually promoted in atrial fibrillation, acute coronary syndrome and other cardiovascular diseases with high incidence.

Uses of Rivaroxaban.

Rivaroxaban, which has been approved for use in adult patients undergoing hip or knee replacement surgery to prevent venous thrombosis (VTE); And treating deep vein thrombosis (DVT) in adults to reduce the risk of DVT recurrence and pulmonary embolism (PE) after acute DVT. Atrial fibrillation is a common arrhythmia that affects up to 10% of people over 75 years of age. The blood of patients with atrial fibrillation is easy to form blood clots and blood clots can fall off and lead to stroke. Rivaroxaban has been approved and is recommended for adult patients with nonvalvular atrial fibrillation to reduce the risk of stroke and systemic embolism.

For adult patients undergoing elective hip or knee replacement surgery to prevent venous thrombosis (VTE).

Drug action of Rivaroxaban.

Rivaroxaban is highly selective and competitively inhibits both free and bound factor Xa as well as prothrombin activity, extending activated partial thromboplastin time (PT) and prothrombin time (aPTT) in a dose-dependent manner. The essential difference between rivaroxaban and sulfodaheparin sodium/heparin is that it does not require the participation of antithrombin III, and can directly antagonize the free and bound factor Xa to reduce the activation of thrombin and thus prolong the clotting time. It not only blocks the formation of blood clots, but also destroys the formed blood clots. Rivaroxaban helps prevent the formation and further progression of blood clots in leg veins that do not flow well back to the heart during hip or knee replacement.

Product Methods of Rivaroxaban.